Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Zidebactam-Cefepime and Metronidazole in Healthy Adults
NCT06806995Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cefepime + zidebactam in bacterial infection, sponsored by Wockhardt. Primary endpoint: Plasma Pharmacokinetics Parameters at Day 7. Started Jan 2025; status: completed.
02
Drugs
cefepime + zidebactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06806995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806995.